Company: BLLN
Filing Date: 2025-10-07
Form Type: S-1
Source: 0001193125-25-233697
Chunk: 338

Company: BillionToOne, Inc.
Filing Date: 2025-10-07
Form: S-1
Chunk 338
---
 - |   |     | $ |       9 |   |
| Supplemental non-cash investing and financing                                                  
 activities:                                                                                    |     |              |        |   |     |   |         |   |
| Right-of-use                                                                                   
 assets obtained in exchange for new finance lease liabilities                                  |     | $            |  2,795 |   |     | $ |     395 |   |
| Purchases of property and equipment in accounts payable and accrued expenses and other current 
 liabilities                                                                                    |     | $            |      - |   |     | $ |   1,001 |   |
| Issuance of Series C-1 redeemable convertible preferred                                        
 stock upon settlement of convertible notes                                                     |     | $            |      - |   |     | $ |  39,886 |   |
| Exercise of stock options for which cash has not been received                                 |     | $            |    102 |   |     | $ |     173 |   |

The accompanying notes are an integral part of these financial statements. F-7

B ILLIONT OO NE, INC.

Notes to Financial Statements

(1) Description of Business

BillionToOne, Inc. (the
“Company”, “we”, or “our”) was formed in 2016, and headquartered in Menlo Park, California. The Company is a precision diagnostics company that quantifies biology to create molecular diagnostics. The
Company’s proprietary molecular counting platform is designed to detect and measure DNA molecules at the single-count level to help improve disease detection. The Company currently applies the proprietary technology to non-invasive prenatal screening (“Prenatal”) and liquid biopsy (“Oncology”).

(2) Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America
(“U.S. GAAP”). Prior to April 2024, the financial statements also included the Company’s wholly owned subsidiary SeqIndia Labs Private Limited which had immaterial activities and was not material to these financial statements and
was divested in April 2024. Accordingly, in 2023, the financial statements were consolidated while in 2024 they were not. All intercompany transactions and balances have been eliminated upon consolidation.

Use of Estimates

The preparation of financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and